CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 380 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $3,020,306 | -93.4% | 44,312 | -93.9% | 0.01% | -93.9% |
| Q4 2023 | $45,503,126 | +3060.9% | 726,887 | +2734.8% | 0.18% | +2457.1% |
| Q2 2023 | $1,439,542 | -51.9% | 25,642 | -61.2% | 0.01% | -53.3% |
| Q1 2023 | $2,990,789 | +197.6% | 66,124 | +329.9% | 0.02% | +200.0% |
| Q3 2022 | $1,005,000 | -88.8% | 15,380 | -89.6% | 0.01% | -89.4% |
| Q2 2022 | $8,999,000 | -62.2% | 148,090 | -61.0% | 0.05% | -65.2% |
| Q1 2022 | $23,805,000 | +45.7% | 379,234 | +75.9% | 0.14% | +51.7% |
| Q4 2021 | $16,340,000 | +5257.4% | 215,629 | +7818.8% | 0.09% | +4350.0% |
| Q3 2021 | $305,000 | -58.9% | 2,723 | -40.6% | 0.00% | -60.0% |
| Q2 2021 | $742,000 | -85.2% | 4,583 | -88.9% | 0.01% | -86.5% |
| Q1 2021 | $5,027,000 | +12.5% | 41,259 | +41.3% | 0.04% | -2.6% |
| Q4 2020 | $4,469,000 | +23.1% | 29,191 | -51.0% | 0.04% | -46.5% |
| Q4 2019 | $3,631,000 | +103.1% | 59,617 | -4.7% | 0.07% | -12.3% |
| Q4 2018 | $1,788,000 | – | 62,580 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |